SC Nivolumab Shows Noninferiority Compared to IV Opdivo (nivolumab) in Advanced or Metastatic ccRCC in CheckMate -67T Trial February 26, 2024
Preliminary DCR of 61% reported in evaluable Ph 2 advanced breast cancer patients treated with Bria-IMT February 26, 2024
Final Results of Ph 3 ASCERTAIN Trial of Oral Decitabine and Cedazuridine Fixed Dose Combination (INQOVI®) in Patients With MDS and CMML published February 16, 2024
FAILED TRIAL: Ph 3 EVOKE-01 study did not meet primary endpoint of OS in previously treated metastatic NSCLC January 31, 2024
Complete Remission Of The Cohort 1 First Patient Treated For R/R B-ALL In Ph 1 Trial Of PMB-CT01 (BAFFR-CAR T Cells) announced January 31, 2024
Opdivo + CABOMETYX Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in 1L Advanced RCC January 31, 2024
KEYTRUDA Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery January 31, 2024
KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With RCC at an Increased Risk of Recurrence Following Nephrectomy January 31, 2024
Imfinzi plus transarterial chemoembolisation (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolisation January 23, 2024
Data from Ph 1b Study of Quemliclustat-Based Regimens Showed Promising OS in Treatment-Naïve Metastatic Pancreatic Cancer January 23, 2024
Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer Provided January 17, 2024
Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia Announced January 10, 2024
Scemblix Shows Superior MMR Rates Vs. SoC TKIs In Ph 3 Trial For Newly Diagnosed Patients With CML January 10, 2024
Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma announced January 10, 2024
Jemperli + Zejula combination significantly improved PFS in primary advanced or recurrent endometrial cancer in RUBY Part 2 Ph 3 trial January 4, 2024
FAILED TRIAL: CARMEN-LC03 trial did not meet dual primary endpoint of improving PFS; tusamitamab ravtansine clinical development program to be discontinued January 4, 2024
Positive Immune Response and Survival Data reported in Completed Ph 1 Study of Galinpepimut-S + Opdivo in Advanced Malignant Pleural Mesothelioma January 4, 2024
Unprecedented Preliminary Survival and Clinical Benefit reported in Antibody-Drug Conjugate (ADC) Refractory Patient Subset treated with Bria-IMT™ regimen January 4, 2024
Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan January 4, 2024
Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin announced January 4, 2024
FAILED TRIAL: RELATIVITY-123 Trial Evaluating the Fixed-Dose Combo of Opdivo + Relatlimab in Previously Treated MSS CRC Patients unlikely to meet primary endpoint, to be discontinued December 19, 2023
mRNA-4157 (V940) + KEYTRUDA Combination Demonstrated Continued Improvement in RFS and DMFS in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA At Three Years December 19, 2023
Complete Response In First Lymphoma Patient Treated With MT-601 Following CAR-T Relapse December 19, 2023
